1. Home
  2. DOUG vs GBIO Comparison

DOUG vs GBIO Comparison

Compare DOUG & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Douglas Elliman Inc.

DOUG

Douglas Elliman Inc.

N/A

Current Price

$2.52

Market Cap

219.1M

Sector

Real Estate

ML Signal

N/A

Logo Generation Bio Co.

GBIO

Generation Bio Co.

N/A

Current Price

$5.38

Market Cap

35.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DOUG
GBIO
Founded
1911
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Building operators
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
219.1M
35.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
DOUG
GBIO
Price
$2.52
$5.38
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$8.88
AVG Volume (30 Days)
300.1K
46.6K
Earning Date
11-04-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,030,928,000.00
$15,270,000.00
Revenue This Year
$17.61
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.67
N/A
52 Week Low
$1.48
$3.00
52 Week High
$3.20
$12.50

Technical Indicators

Market Signals
Indicator
DOUG
GBIO
Relative Strength Index (RSI) 44.96 50.70
Support Level $2.66 $5.20
Resistance Level $2.90 $5.54
Average True Range (ATR) 0.11 0.24
MACD -0.00 0.04
Stochastic Oscillator 2.53 59.32

Price Performance

Historical Comparison
DOUG
GBIO

About DOUG Douglas Elliman Inc.

Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: